Circulating Tumor DNA
Cross-source consensus on Circulating Tumor DNA from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Patients who were ctDNA-positive after surgery had higher recurrence risk than ctDNA-negative patients. — Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care
- ctDNA affected recurrence risk but did not alter surveillance schedules in the model. — Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care
- ctDNA was modeled as a marker of residual tumor cells after surgery. — Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care
- The model improved on earlier CRC models by including ctDNA-related recurrence risk. — Microsimulation model to identify suboptimal recurrence detection in patients with colorectal cancer following the current standard of care